Congress orders study to weaken drug manufacturing rules—without assessing public health cost

What it does

This bill directs the Government Accountability Office (GAO) to study what federal regulations are slowing down or making more expensive the construction and expansion of pharmaceutical manufacturing plants in the United States, and to compare those barriers to regulations in other countries. The GAO will interview industry stakeholders, assess the time and cost impact of environmental and other rules, and recommend ways regulators could speed up approvals and inspections to make the U.S. a more competitive location for drug manufacturing.

Why we flagged it

The bill's core function is a study, not direct deregulation. However, the framing—asking how to make U.S. rules 'less burdensome' relative to other countries and requesting 'streamlining' recommendations—signals intent to reduce regulatory friction, likely environmental and safety reviews. This is a soft-power deregulation bill disguised as fact-finding.

What the text implies

• The study's focus on comparing U.S. regulations unfavorably to other countries (which may have weaker environmental or safety standards) may be used to justify rollbacks of FDA, EPA, or OSHA rules without explicit legislative action.
• Recommendations to 'expedite reviews, inspections, and approvals' could lead to reduced scrutiny of manufacturing practices, potentially increasing risk of contamination, quality failures, or worker safety issues.
• The bill does not require the study to assess PUBLIC health or safety impacts of deregulation—only industry cost and time burdens—creating an asymmetric analysis favoring industry interests.
• Engagement with 'stakeholders' (industry-speak for manufacturers) without explicit inclusion of public health advocates, environmental groups, or worker safety representatives may bias the study toward industry-friendly recommendations.

Who it affects

A study identifying regulatory barriers to domestic drug manufacturing could support public health by strengthening supply chain resilience and reducing drug shortages. However, the bill's framing—comparing U.S. rules unfavorably to other countries and asking how to 'streamline' environmental and safety reviews—suggests the intent is to weaken protections. Citizens benefit from both affordable drugs AND safe manufacturing practices; this bill risks trading the latter for the former without expli

Who stands to gain

• pharmaceutical manufacturers
• contract manufacturing organizations (CMOs)
• pharmaceutical equipment suppliers

Named in the bill

Government Accountability Office (GAO), Comptroller General, FDA, EPA, OSHA, pharmaceutical manufacturers, pharmaceutical supply chain

Where it stands

1 cosponsor: 1 Republicans.

• Feb 18, 2025 — Introduced · Congress.gov: “Introduced in House”
• Feb 18, 2025 — Referred to House Committee on Energy and Commerce · Congress.gov: “Referred to the House Committee on Energy and Commerce”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.